Last June, Auxogyn's Eeva System was the first to be cleared by FDA to aid in IVF embryo selection in combination with traditional morphology. Now the startup has raised $34.3 million, out of a planned $41 million, financing round to start commercializing this test, according to an SEC filing.
The FDA gave de novo approval to Menlo Park-based Auxogyn's Eeva System, a fertility-enhancing diagnostic test currently available in Europe and Canada.
Germany's Merck KGaA signed a licensing agreement with Menlo Park, CA-based Auxogyn to sell its fertility-enhancing diagnostic test in Europe and Canada with an option to extend the agreement to other countries.
Auxogyn has reeled in $18 million in Series B funding to help bring its diagnostic test to evaluate embryo viability during in vitro fertilization to the regulatory finish line in a big advance for the field.